Gynecologic Cancer News

Tisotumab vedotin-tftv prolonged OS compared with chemotherapy alone among women with recurrent or metastatic cervical cancer, according to the agent’s manufacturers.

In the ONCO-DVT trial, patients with cancer and isolated distal deep vein thrombosis had fewer thrombotic events at 1 year with 12-month vs. 3-month edoxaban therapy, a finding that could change clinical guidance, according to a speaker.

Combining weight-based dosing and single-use vial sharing within individual Veterans Affairs hospitals could reduce immune checkpoint inhibitor spending by millions annually, according to study results published in Health Affairs.

After decades of developmental challenges, antibody-drug conjugates have emerged as potentially less toxic and more effective treatment options for a variety of malignancies.

The prevalence of distress among women with late-stage gynecologic cancers calls for well-designed studies to assess the safety and efficacy of psychedelics for this patient population, according to authors of a published commentary.

Identification of inherited genetic mutations that elevate cancer risk and may be susceptible to targeted therapies has transformed oncology care.

An analysis of individuals diagnosed with second primary cancers showed Black individuals exhibited considerably higher risks for cancer-related and cardiovascular-related deaths than white individuals.

A 6-month aerobic exercise intervention significantly improved self-reported chemotherapy-induced peripheral neuropathy among women who underwent chemotherapy for ovarian cancer, according to study results published in JAMA Network Open.

The University of Texas MD Anderson Cancer Center has retained its distinction as the No. 1 cancer hospital in the country.

The FDA approved dostarlimab in combination with chemotherapy for certain women with endometrial cancer.